Technology
Our Approach
We focus on endogenous neuroprotection solutions, leveraging academic research to develop new therapeutic interventions. Our pioneering work on HAEE represents a significant leap forward in enhancing neuronal stability and overall brain health.
​
We are actively seeking strategic collaborations and scientific partnerships to accelerate HAEE’s clinical translation — including formulation research, biomarker validation, and neuroprotective program alignment with industry and academic partners.
Our Vision
Proteonix is advancing, HAEE, a first-in-class endogenous peptide platform emerging from translational research in neurodegenerative diseases and psychiatry.
Recent analytical studies confirmed HAEE as a natural plasma component with measurable deficiency in cognitive disorders, suggesting a novel pathway for restoring neuronal equilibrium in response to stress.
​
Latest Preprint
Our Research
​
Our latest preprint introduces HAEE, an endogenous plasma peptide identified through analytical studies exploring neuroprotective pathways.
The research outlines HAEE’s potential role as a measurable biochemical indicator of adaptive balance in the brain, representing a step toward evidence-based peptide innovation.